New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome

Publisher： Bentham Science Publishers

E-ISSN： 1875-6417|9|2|137-145

ISSN： 1573-3998

Source： Current Diabetes Reviews, Vol.9, Iss.2, 2013-03, pp. : 137-145

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Carbohydrate restriction as the default treatment for type 2 diabetes and metabolic syndrome

By Feinman Richard   Volek Jeff  

Scandinavian Cardiovascular Journal, Vol. 42, Iss. 4, 2008-01 ,pp. : 256-263

Informa Healthcare

Access to resources Recommend Favorite

Review of Evidence that Epidemics of Type 1 Diabetes and Type 2 Diabetes/ Metabolic Syndrome are Polar Opposite Responses to Iatrogenic Inflammation

By  

Current Diabetes Reviews, Vol. 8, Iss. 6, 2012-11 ,pp. : 413-418

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD

By  

Current Cardiology Reviews, Vol. 6, Iss. 2, 2010-05 ,pp. : 112-118

Bentham Science Publishers

Access to resources Recommend Favorite

Dual Peroxisome Proliferator-Activated Receptor-α/ Agonists: In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome

By Pershadsingh Harrihar A.  

Treatments in Endocrinology, Vol. 5, Iss. 2, 2006-01 ,pp. : 89-99

Adis International

Access to resources Recommend Favorite

The Metabolic Syndrome and Type 2 Diabetes: Epidemiological Figures and Country Specificities

By  

Cerebrovascular Diseases, Vol. 20, Iss. 1, 2005-11 ,pp. : 2-8

Karger

Access to resources Recommend Favorite